Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer

被引：0
|
作者：
Musolino, Antonino [1 ]
Guarneri, Valentina [2 ]
Naldi, Nadia [1 ]
Bortesi, Beatrice [1 ]
Boggiani, Daniela [1 ]
Sgargi, Paolo [1 ]
Generali, Daniele G. [3 ]
Piacentini, Federico [4 ]
Dieci, Maria V. [2 ]
Ambroggi, Massimo [5 ]
Cagossi, Katia [6 ]
Gianni, Lorenzo [7 ]
Sarti, Samanta [8 ]
Bisagni, Giancarlo [9 ]
Frassoldati, Antonio [10 ]
Conte, Pierfranco [2 ]
Ardizzoni, Andrea [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
[2] Univ Padua, Ist Oncol Veneto IRCCS, I-35100 Padua, Italy
[3] AO Ist Ospitalieri Cremona, Cremona, Italy
[4] Modena Univ Hosp, Modena, Italy
[5] Hosp Piacenza, Piacenza, Italy
[6] Ramazzini Hosp, Carpi, Italy
[7] Osped Infermi, Rimini, Italy
[8] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[9] Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy
[10] Ferrara Univ Hosp, Ferrara, Italy
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-06-23
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
    Musolino, A.
    Naldi, N.
    Dieci, M. V.
    Zanoni, D.
    Rimanti, A.
    Boggiani, D.
    Sgargi, P.
    Generali, D. G.
    Piacentini, F.
    Ambroggi, M.
    Cagossi, K.
    Gianni, L.
    Sarti, S.
    Bisagni, G.
    Ardizzoni, A.
    Conte, P. F.
    Guarneri, V.
    PHARMACOGENOMICS JOURNAL, 2016, 16 (05): : 472 - 477
  • [2] Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
    A Musolino
    N Naldi
    M V Dieci
    D Zanoni
    A Rimanti
    D Boggiani
    P Sgargi
    D G Generali
    F Piacentini
    M Ambroggi
    K Cagossi
    L Gianni
    S Sarti
    G Bisagni
    A Ardizzoni
    P F Conte
    V Guarneri
    The Pharmacogenomics Journal, 2016, 16 : 472 - 477
  • [3] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [4] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    V Guarneri
    A Frassoldati
    F Piacentini
    K Cagossi
    L Cavanna
    A Michelotti
    G Jovic
    S Giovannelli
    G Ficarra
    C Oliva
    P Conte
    Breast Cancer Research, 9
  • [5] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    Guarneri, V.
    Frassoldati, A.
    Piacentini, F.
    Cagossi, K.
    Cavanna, L.
    Michelotti, A.
    Jovic, G.
    Giovannelli, S.
    Ficarra, G.
    Oliva, C.
    Conte, P.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [6] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [7] Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
    Musolino, Antonino
    Naldi, Nadia
    Bortesi, Beatrice
    Pezzuolo, Debora
    Capelletti, Marzia
    Missale, Gabriele
    Laccabue, Diletta
    Zerbini, Alessandro
    Camisa, Roberta
    Bisagni, Giancarlo
    Neri, Tauro Maria
    Ardizzoni, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1789 - 1796
  • [8] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
    Printz, Carrie
    CANCER, 2020, 126 (09) : 1827 - 1827
  • [9] Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
    Takada, Masahiro
    Sugimoto, Masahiro
    Masuda, Norikazu
    Iwata, Hiroji
    Kuroi, Katsumasa
    Yamashiro, Hiroyasu
    Ohno, Shinji
    Ishiguro, Hiroshi
    Inamoto, Takashi
    Toi, Masakazu
    ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [10] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
12345